BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 16503860)

  • 1. Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma.
    Kose MF; Meydanli MM; Tulunay G
    Expert Rev Anticancer Ther; 2006 Mar; 6(3):437-43. PubMed ID: 16503860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of platinum-sensitive recurrent ovarian cancer.
    Pfisterer J; Ledermann JA
    Semin Oncol; 2006 Apr; 33(2 Suppl 6):S12-6. PubMed ID: 16716798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
    Pfisterer J; Plante M; Vergote I; du Bois A; Hirte H; Lacave AJ; Wagner U; Stähle A; Stuart G; Kimmig R; Olbricht S; Le T; Emerich J; Kuhn W; Bentley J; Jackisch C; Lück HJ; Rochon J; Zimmermann AH; Eisenhauer E; ; ;
    J Clin Oncol; 2006 Oct; 24(29):4699-707. PubMed ID: 16966687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer.
    Sufliarsky J; Chovanec J; Svetlovska D; Minarik T; Packan T; Kroslakova D; Lalabova R; Helpianska L; Horvathova D; Sevcik L; Spacek J; Laluha A; Tkacova V; Malec V; Rakicka G; Magdin D; Jancokova I; Dorr A; Stresko M; Habetinek V; Koza I
    Neoplasma; 2009; 56(4):291-7. PubMed ID: 19473054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer.
    Pfisterer J; Vergote I; Du Bois A; Eisenhauer E; ; ;
    Int J Gynecol Cancer; 2005; 15 Suppl 1():36-41. PubMed ID: 15839957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
    Edwards SJ; Barton S; Thurgar E; Trevor N
    Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study).
    Fujiwara H; Ushijima K; Nagao S; Takei Y; Shimada M; Takano M; Yoshino K; Kawano Y; Hirashima Y; Nagase S; Nishio S; Nishikawa T; Ito K; Shoji T; Kimura E; Takano T; Sugiyama T; Kigawa J; Fujiwara K; Suzuki M
    Int J Clin Oncol; 2019 Oct; 24(10):1284-1291. PubMed ID: 31127479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
    Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W
    Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of chemotherapy according to
    Brouillard-Saby F; Saint-Martin C; Ray-Coquard I; Gladieff L; Pomel C; Colombo PE; Classe JM; Chevrier M; Joly F; De la Motte Rouge T; Floquet A; Sabatier R; Barranger E; Costaz H; Leblanc E; Marchal F; Pautier P; Bosquet L; Rodrigues M
    Int J Gynecol Cancer; 2023 Apr; 33(4):577-584. PubMed ID: 36631150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine and carboplatin in second-line ovarian cancer.
    Ozols RF
    Semin Oncol; 2005 Aug; 32(4 Suppl 6):S4-8. PubMed ID: 16143161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients.
    Safra T; Asna N; Veizman A; Shpigel S; Matcejevsky D; Inbar M; Grisaru D
    Anticancer Drugs; 2014 Mar; 25(3):340-5. PubMed ID: 24185383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis.
    Berg T; Nøttrup TJ; Roed H
    Gynecol Oncol; 2019 Dec; 155(3):530-537. PubMed ID: 31604664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma.
    Hansen SW
    Semin Oncol; 2002 Feb; 29(1 Suppl 1):17-9. PubMed ID: 11840416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of gemcitabine in ovarian cancer treatment.
    Lorusso D; Di Stefano A; Fanfani F; Scambia G
    Ann Oncol; 2006 May; 17 Suppl 5():v188-94. PubMed ID: 16807454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
    Pitakkarnkul S; Tangjitgamol S; Srijaipracharoen S; Manusirivithaya S; Pataradool K; Prutthiphongsit W; Khunnarong J; Thavaramara T
    Asian Pac J Cancer Prev; 2013; 14(4):2421-7. PubMed ID: 23725151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study.
    Papadimitriou CA; Fountzilas G; Aravantinos G; Kalofonos C; Moulopoulos LA; Briassoulis E; Gika D; Dimopoulos MA;
    Gynecol Oncol; 2004 Jan; 92(1):152-9. PubMed ID: 14751151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of recurrent disease: randomized trials of monotherapy versus combination chemotherapy.
    González-Martín A;
    Int J Gynecol Cancer; 2005; 15 Suppl 3():241-6. PubMed ID: 16343239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma.
    Villella J; Marchetti D; Odunsi K; Rodabaugh K; Driscoll DL; Lele S
    Gynecol Oncol; 2004 Dec; 95(3):539-45. PubMed ID: 15581960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.